Summary of upcoming milestones from Bioshares report which is very positive on Pharmaxis:
The LOXL2 program which is ready for Phase II assessment and partnering
A Phase IIa study in diabetic retinopathy (conducted by Boehringer Ingelheim) with results in H2
A Phase II systemic LOX inhibition study in myelofibrosis (H2), with inhibition of LOX, LOXL1, LOXL2, LOXL3 and the LOXL4 enzymes involved in severe fibrotic conditions
A Phase I topical LOX inhibition study in scar treatment (H2), and....
US FDA approval of Bronchitol for the treatment of cystic fibrosis in the US (H2) which will include a US$10 million milestone payment to Pharmaxis from Chiesi Farmaceutica
Great risk/reward at current price.
Summary of upcoming milestones from Bioshares report which is...
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
0.001(6.25%) |
Mkt cap ! $20.29M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.7¢ | 1.6¢ | $1.248K | 76.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1214731 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 876421 | 8 |
View Market Depth
| Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.7¢ |
Change
0.001 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 1.7¢ | 1.7¢ | 1.7¢ | 24111 | ||
| Last updated 15.59pm 01/05/2024 ? | |||||
| SNT (ASX) Chart |